The Journal of Nuclear Medicine最新文献

{"title":"Summary Report of the SNMMI AI Task Force Radiomics Challenge 2024","authors":"Ronald Boellaard, Arman Rahmim, Jacoba J. Eertink, Ulrich Duehrsen, Lars Kurch, Pieternella J. Lugtenburg, Sanne E. Wiegers, Gerben J.C. Zwezerijnen, Josée M. Zijlstra, Martijn W. Heymans, Irène Buvat","doi":"10.2967/jnumed.124.269425","DOIUrl":"https://doi.org/10.2967/jnumed.124.269425","url":null,"abstract":"<p>In medical imaging, challenges are competitions that aim to provide a fair comparison of different methodologic solutions to a common problem. Challenges typically focus on addressing real-world problems, such as segmentation, detection, and prediction tasks, using various types of medical images and associated data. Here, we describe the organization and results of such a challenge to compare machine-learning models for predicting survival in patients with diffuse large B-cell lymphoma using a baseline ¹⁸F-FDG PET/CT radiomics dataset. <b>Methods:</b> This challenge aimed to predict progression-free survival (PFS) in patients with diffuse large B-cell lymphoma, either as a binary outcome (shorter than 2 y versus longer than 2 y) or as a continuous outcome (survival in months). All participants were provided with a radiomic training dataset, including the ground truth survival for designing a predictive model and a radiomic test dataset without ground truth. Figures of merit (FOMs) used to assess model performance were the root-mean-square error for continuous outcomes and the C-index for 1-, 2-, and 3-y PFS binary outcomes. The challenge was endorsed and initiated by the Society of Nuclear Medicine and Molecular Imaging AI Task Force. <b>Results:</b> Nineteen models for predicting PFS as a continuous outcome from 15 teams were received. Among those models, external validation identified 6 models showing similar performance to that of a simple general linear reference model using SUV and total metabolic tumor volumes (TMTV) only. Twelve models for predicting binary outcomes were submitted by 9 teams. External validation showed that 1 model had higher, but nonsignificant, C-index values compared with values obtained by a simple logistic regression model using SUV and TMTV. <b>Conclusion:</b> Some of the radiomic-based machine-learning models developed by participants showed better FOMs than did simple linear or logistic regression models based on SUV and TMTV only, although the differences in observed FOMs were nonsignificant. This suggests that, for the challenge dataset, there was limited or no value seen from the addition of sophisticated radiomic features and use of machine learning when developing models for outcome prediction.</p>","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"48 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144278436","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preirradiation of Spheroids with 225Ac-Trastuzumab Improves Penetration of 225Ac-Liposomes and MIRDcell Predictions of Responses to Drug Cocktails","authors":"Hima Tallam, Rajiv Nair, Aira Sarkar, Sumudu Katugampola, Stavroula Sofou, Roger W. Howell","doi":"10.2967/jnumed.124.269273","DOIUrl":"https://doi.org/10.2967/jnumed.124.269273","url":null,"abstract":"<sec><st>Visual Abstract</st><p><fig loc=\"float\"><link locator=\"jnumed.124.269273absf1\"></fig></p></sec>","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"64 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144278437","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Translational Potential of Fluorescent PARP1 Inhibitor as a Molecular Contrast Agent for Diagnosis of Basal Cell Carcinoma","authors":"Miriam Ricanati, Ucalene Harris, Neil M. Neumann, Banu Farabi, Nicholas Kurtansky, Anthony Rossi, Chih-Shan J. Chen, Melissa P. Pulitzer, Milind Rajadhyaksha, Stephen Dusza, Ashish Dhir, Manu Jain","doi":"10.2967/jnumed.124.269428","DOIUrl":"https://doi.org/10.2967/jnumed.124.269428","url":null,"abstract":"<sec><st>Visual Abstract</st><p><fig loc=\"float\"><link locator=\"jnumed.124.269428absf1\"></fig></p></sec>","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"89 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144278438","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of 134Ce/134La-PSMA-617 for PET Imaging and Auger Electron Therapy of Prostate Cancer","authors":"Kondapa Naidu Bobba, Anju Wadhwa, Anil P. Bidkar, Athira Raveendran, Luis Garcia, Nancy Greenland, David M. Wilson, Youngho Seo, Henry F. VanBrocklin, Robert R. Flavell","doi":"10.2967/jnumed.125.269751","DOIUrl":"https://doi.org/10.2967/jnumed.125.269751","url":null,"abstract":"<sec><st>Visual Abstract</st><p><fig loc=\"float\"><link locator=\"jnumed.125.269751absf1\"></fig></p></sec>","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"4 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144278432","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dual-Tracer Imaging on a Long–Axial-Field-of-View PET: A Proof-of-Principle Study with [18F]FGln and [18F]FDG","authors":"Daniel Kwon, Elizabeth J. Li, Christina Dulal, Margaret Daube-Witherspoon, Varsha Viswanath, Anthony J. Young, Raheema A. Damani, Jason Hou-Liu, Elizabeth S. McDonald, David A. Mankoff, Joel S. Karp, Austin R. Pantel","doi":"10.2967/jnumed.124.268831","DOIUrl":"https://doi.org/10.2967/jnumed.124.268831","url":null,"abstract":"<sec><st>Visual Abstract</st><p><fig loc=\"float\"><link locator=\"jnumed.124.268831absf1\"></fig></p></sec>","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"36 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144278430","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Use of PSMA PET/CT Improves Overall Survival in Men with Biochemically Recurrent Prostate Cancer Treated with Salvage Radiotherapy: Real-World Data from an Entire Country","authors":"Anna W. Mogensen, Christian Torp-Pedersen, Mette Nørgaard, Lars J. Petersen, Mette Moe, Helle D. Zacho","doi":"10.2967/jnumed.125.269996","DOIUrl":"https://doi.org/10.2967/jnumed.125.269996","url":null,"abstract":"<p>International guidelines recommend salvage radiotherapy (sRT) as a curative treatment for men with biochemically recurrent prostate cancer after radical prostatectomy. Prostate-specific membrane antigen (PSMA) PET/CT has demonstrated high sensitivity for localizing recurrent disease at low prostate-specific antigen levels, enabling improved treatment decision-making. However, few studies have investigated the impact of pre-sRT PSMA PET/CT on patient-relevant outcomes, that is, recurrence-free and overall survival. Moreover, no comparison exists of overall survival between patients who underwent PSMA PET/CT and those who did not, before sRT. <strong>Methods:</strong> This study used real-world data (obtained from routine clinical practice) of all patients treated with sRT in Denmark from 2015 through 2023. Patients were categorized according to whether they underwent pretreatment PSMA PET/CT. Our main objective was to compare overall survival up to 5 y after completion of sRT. Biochemical recurrence–free survival (BRFS) was included as a secondary outcome. Only patients with a prostate-specific antigen value of 0.2–1.0 ng/mL were included. <strong>Results:</strong> In total, 844 patients were treated with sRT during the study period, of whom 308 (36.5%) underwent pretreatment PSMA PET/CT. The analysis revealed greater overall survival for patients who underwent PSMA PET/CT before sRT than for patients who did not. The 1-, 2-, and 5-y survival rates for PSMA PET/CT patients were 100% (95% CI, 100%–100%), 99.5% (95% CI, 98.6%–100%), and 98.1% (95% CI, 96%–100%), respectively, versus 99% (95% CI, 98.2%–99.9%), 97.8% (95% CI, 96.5%–99.1%), and 93.8% (95% CI, 91.5%–96.2%), respectively, for non-PSMA PET/CT patients (crude hazard ratio, 3.31 [95% CI, 1.01–10.88]; <em>P</em> = 0.0486). Comparatively, the 3-y BRFS rate was consistent with overall survival: 74.9% (95% CI, 68.5%–81.3%) for PSMA PET/CT patients and 69.4% (95% CI, 65.2%–73.7%) for non-PSMA PET/CT patients, with a hazard ratio of 1.53 (95% CI, 1.07–2.19; <em>P</em> = 0.0187). <strong>Conclusion:</strong> PSMA PET/CT use before sRT was associated with improved overall survival and BRFS.</p>","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"26 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144278439","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Imaging Efficacy of [18F]CTT1057 PET for the Detection of PSMA-Positive Tumors Using Histopathology as Standard of Truth: Results from the GuideView Phase 2/3 Prospective Multicenter Study","authors":"Andrei Iagaru, Jose F. Suarez, Spencer Behr, Rahul Aggarwal, Pilar Paredes, Nicolo Buffi, Thomas Penhoat, Francesco Ceci, Jochen Walz, Nicolas Doumerc, Medge Coulanges, Zhongying Xu, Christelle Seigne, Celine Wilke, Ana M. Catafau, Stefano Fanti, Tobias Maurer, on behalf of the GuideView study investigators","doi":"10.2967/jnumed.124.269007","DOIUrl":"https://doi.org/10.2967/jnumed.124.269007","url":null,"abstract":"<sec><st>Visual Abstract</st><p><fig loc=\"float\"><link locator=\"jnumed.124.269007absf1\"></fig></p></sec>","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"5 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144228839","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment Response Evaluation in Prostate Cancer Using PSMA PET/CT","authors":"Andrei Gafita, Jennifer A. Schroeder, Francesco Ceci, Jorge D. Oldan, Amir H. Khandani, Frederic E. Lecouvet, Lilja B. Solnes, Steven P. Rowe","doi":"10.2967/jnumed.124.268071","DOIUrl":"https://doi.org/10.2967/jnumed.124.268071","url":null,"abstract":"<p>In recent years, there has been a headlong rush into the use of prostate-specific membrane antigen (PSMA)&ndash;targeted PET for the staging and restaging of men with prostate cancer (PC). To date, there have been regulatory approvals for PSMA PET for purposes of initial staging, recurrence, and establishing eligibility for PSMA-targeted radiopharmaceutical therapy. Conventional imaging modalities, including bone scan and CT, are inadequate for identifying sites of PC in a variety of clinical scenarios. Further, current standardized response assessment approaches based on either conventional imaging or PET radiotracers that lack sensitivity for PC are inappropriate for response assessment in men with PC. There is currently no specific regulatory approval for the use of PSMA PET for response assessment. In the context of the use of PSMA-targeted radiopharmaceutical therapy and other cytotoxic therapeutic approaches, both the PSMA PET progression criteria and RECIP 1.0 have been shown to have value and to provide prognostic information. However, the role of those criteria is less clear for patients who are being treated with agents targeting the androgen signaling axis, given variable changes in PSMA expression. Ultimately, there may be key roles for machine learning and artificial intelligence in identifying imaging biomarkers based on changes in PSMA PET uptake during therapy.</p>","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"70 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144228833","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cost-Effectiveness of [177Lu]Lu-DOTATATE for the Treatment of Newly Diagnosed Advanced Gastroenteropancreatic Neuroendocrine Tumors: An Analysis Based on Results of the NETTER-2 Trials","authors":"Adrien Holzgreve, Lena M. Unterrainer, Maximilian Tiling, Nabeel Mansour, Christine Spitzweg, Matthias Brendel, Jens Ricke, Marcus Unterrainer, Wolfgang G. Kunz, Dirk Mehrens","doi":"10.2967/jnumed.124.269416","DOIUrl":"https://doi.org/10.2967/jnumed.124.269416","url":null,"abstract":"<sec><st>Visual Abstract</st><p><fig loc=\"float\"><link locator=\"jnumed.124.269416absf1\"></fig></p></sec>","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"19 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144228838","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quantitative [89Zr]Zr-Trastuzumab PET and Diffusion- Weighted MRI for Characterization of Metastatic HER2-Positive Breast Cancer with PET/MRI","authors":"Ameer Mansur, Jonathan E. McConathy, Erica Stringer-Reasor, Gabrielle Rocque, Katia Khoury, Noon Eltoum, Moozhan Nikpanah, Jennifer Bartels, Brian Wright, Nusrat Jahan, Denise Jeffers, Suzanne E. Lapi, Anna G. Sorace","doi":"10.2967/jnumed.124.268931","DOIUrl":"https://doi.org/10.2967/jnumed.124.268931","url":null,"abstract":"<sec><st>Visual Abstract</st><p><fig loc=\"float\"><link locator=\"jnumed.124.268931absf1\"></fig></p></sec>","PeriodicalId":22820,"journal":{"name":"The Journal of Nuclear Medicine","volume":"54 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144228834","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}